How did EBOS Group (ASX:EBO) perform in the first half of FY26?

EBOS Group reported a solid HY26 result for the period ending 31 December 2025, featured by a 13% increase in revenue. Underlying EBITDA grew by 3.2% to $300 million, driven by disciplined cost management and the commissioning of strategic investments.

Which business segment drove the most growth for EBOS Group (ASX:EBO)?

The Animal Care segment was the standout performer, with EBITDA surging 15.1% to $68 million. This growth was primarily fuelled by strong performance from the company's branded products and the successful integration of the SVS acquisition.

What is the current EBITDA guidance for EBOS Group (ASX:EBO)?

Management has reaffirmed its full-year FY26 EBITDA guidance following the HY26 results. The company expects an earnings uplift in the second half of the year (H2 FY26) as several strategic initiatives reach maturity.

How does the distribution centre renewal program affect EBOS Group's margins?

EBOS has reached a key milestone with its largest distribution centre now fully operational. As these assets transition from the commissioning phase into a "steady state," the company expects to realise meaningful efficiency gains and operational productivity.

What are the key catalysts for EBOS Group (ASX:EBO) in H2 FY26?

Growth in the second half of the financial year is expected to be supported by the newly acquired MediAdvice pharmacy network and a robust product pipeline in Animal Care.

Is EBOS Group (ASX:EBO) a defensive or cyclical investment after this news?

The results reinforce EBOS's profile as a defensive growth stock due to its essential roles in healthcare distribution and pet care. High demand in these sectors tends to be less sensitive to consumer spending pullbacks.

What are the main risks for EBOS Group (ASX:EBO) shareholders now?

The primary risk lies in the execution of the final stages of the capital investment cycle and the integration of the MediAdvice network. While management is confident, any delays in reaching "steady state" efficiency at new distribution centres could pinch margins.

Image for illustrative purposes only. Not a real photo.

EBOS Group shares rise on strong H1 revenue growth

Written by Brie CarterPublished Feb 25, 2026, 4:03 AMLast Updated Jul 6, 2026, 10:45 AM

EBOS Group (ASX:EBO) announced a robust financial performance for the half-year ended Dec. 31, 2025, headlined by a 13% increase in revenue.

The healthcare and animal care distributor reported that underlying EBITDA rose by 3.2% to $300 million, a result the company attributes to disciplined cost management and the strategic commissioning of recent investments.

The group's Animal Care segment was a standout performer, with EBITDA surging 15.1% to $68 million.

The growth was fuelled by strong branded performance and the successful integration of SVS.

Meanwhile, the healthcare segment remained the primary contributor, posting an EBITDA of $254 million, representing a 1.3% increase.

The steady growth was supported by high demand across key markets and a focus on operational productivity.

CEO Adam Hall expressed confidence in the company’s trajectory, noting that the results demonstrate the resilience of EBOS’s diversified portfolio.

Key operational milestones included progress on the distribution centre renewal program, with the company's largest site now fully operational. This transition into "steady state" is expected to yield significant efficiency gains in the second half of the year.

Looking ahead, EBOS has reaffirmed its FY26 EBITDA guidance.

The company anticipates further uplift in H2 FY26, supported by the newly acquired MediAdvice pharmacy network, a strong product pipeline in Animal Care, and the nearing completion of its current capital investment cycle.

At the time of reporting, EBOS Group's share price was $20.26.

EBOS Group shares rise on strong H1 revenue growth

Frequently asked questions

Assets related to this article